SCHEMBL3527997

SCHEMBL3527997

CCOC(=O)C(C)OCc1cc2cc(C(F)(F)F)ccc2n1S(=O)(=O)c1ccc2ncsc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 13/20 0.56
PPARA Q07869 11/20 0.56
PPARD Q03181 11/20 0.56
NTRK1 P04629 1/20 0.38
NTRK2 Q16620 1/20 0.38
ALDH1A1 P00352 2/20 0.36
PKM P14618 1/20 0.36
POLB P06746 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
HPGD P15428 1/20 0.34
CASP1 P29466 1/20 0.34
HTT P42858 1/20 0.34
CASP7 P55210 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
S1PR1 P21453 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3523785 0.92 PPARG (0.61) PPARGPPARAPPARDNTRK1NTRK2
SCHEMBL3527627 0.88 PPARG (0.50) PPARGPPARAPPARDALDH1A1PKM
SCHEMBL3524079 0.88 PPARG (0.62) PPARGPPARAPPARDALDH1A1PKM
SCHEMBL3522131 0.88 PPARG (0.62) PPARGPPARAPPARDALDH1A1PKM
SCHEMBL3529433 0.83 PPARG (0.59) PPARGPPARAPPARD
SCHEMBL3523262 0.83 PPARG (0.61) PPARGPPARAPPARDNTRK1NTRK2
SCHEMBL3529885 0.82 PPARG (0.53) PPARGPPARAPPARDPKMRAB9A
SCHEMBL3520589 0.81 PPARG (0.57) PPARGPPARAPPARDNTRK1NTRK2
SCHEMBL3527558 0.81 PPARG (0.63) PPARGPPARAPPARD
SCHEMBL3530671 0.81 PPARG (0.48) PPARGPPARAPPARDALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP PPARG 1018/4885PPARA 847/4885PPARD 677/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG PPARG 3/4885PPARA 2/4885PPARD 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.